We came across a bearish thesis on uniQure N.V. on augur’s substack. In this article, we will summarize the bulls’ thesis on QURE. uniQure N.V.'s share was trading at $27.51 as of November 28th. QURE’s forward P/E was 27.93 according to Yahoo Finance.
[caption id="attachment_575754" align="aligncenter" width="750"]uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. QURE’s AMT-130 gene therapy faces significant scientific and strategic challenges in the rapidly...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.